Comparative effectiveness research has assumed an increasing role in drug coverage and, in some cases, pricing decisions in Europe, as decision-makers seek to obtain better value for money. This issue brief examines the use of such research in six countries—Denmark, England, France, Germany, the Netherlands, and Sweden. With comparative effectiveness research gaining traction in the United States, these international experiences offer insights and potential lessons.